iPath Goldman Sachs Barclays Bank PLC iPath Exchange Traded Notes Linked to the CBOE S&P 500 BuyWrite Index Structured Product (BWV): Price and Financial Metrics ETF
BWV Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market
| Current price | $0.80 | 52-week high | $8.00 |
| Prev. close | $0.79 | 52-week low | $0.76 |
| Day low | $0.77 | Volume | 20,090 |
| Day high | $0.82 | Avg. volume | 1,042,255 |
| 50-day MA | $1.00 | Dividend yield | N/A |
| 200-day MA | $1.39 |
BWV Stock Price Chart Interactive Chart >
iPath Goldman Sachs Barclays Bank PLC iPath Exchange Traded Notes Linked to the CBOE S&P 500 BuyWrite Index Structured Product (BWV) ETF Bio
The investment objective of the iPath CBOE S&P 500 BuyWrite ETN is to provide investors with exposure to the CBOE S&P 500 BuyWrite Index. The Index is designed to measure the total rate of return on a hypothetical "buy-write”, or "covered call", strategy on the S&P 500® Index. This strategy consists of a hypothetical portfolio consisting of a "long” position indexed to the S&P 500 Index and the sale of a succession of a one-month, at-the-money S&P 500® call options that are listed on the Chicago Board Options Exchange.
BWV ETF Info
| Issuer | |
| Expense Ratio | % |
| Asset Class | |
| Sector | Large Cap Blend ETFs |
| Assets Under Management (AUM) | N/A |
| Net Asset Value (NAV) | $0.00 |
| Options? | No |
| Total Holdings | N/A |
Latest BWV News From Around the Web
Below are the latest news stories about BLUE WATER BIOTECH INC that investors may wish to consider to help them evaluate BWV as an investment opportunity.
Blue Water Vaccines GAAP EPS of -$0.18 misses by $0.03
|
Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business HighlightsCINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced its financial results for the quarter ended March 31, 2023 and provided an update on recent business developments and Company progress. Blue Water Biotech is a biological and pharmaceutical technology company developing multiple preclinical vaccine candidates across various infectious diseases and owns the FDA-approved benign hy |
Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NYCINCINNATI, May 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biopharmaceutical company developing transformational therapies to address significant global health challenges, today announced that Blue Water management will present at the JMP Securities Life Sciences Conference at the New York Hilton Midtown on Monday, May 15th at 3:30pm EDT. Session details are as follows: Date:Monday, May 15th, 2023Time:3:30pm EDTLocation:New York Hilton Midtown, Room |
Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical OfficerCINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced the appointment of Jay Newmark, M.D., MBA as the Company’s Chief Medical Officer. Dr. Newmark is a board-certified urologist with over 30 years of experience managing Men’s Health issues, including benign prostatic hyperplasia (“BPH”). Blue Water currently owns ENTADFI®, an FDA-approved treatment for BPH that counteracts negat |
Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®CINCINNATI, April 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced that Blue Water management will attend the American Urological Association (“AUA”) Annual Meeting 2023 in Chicago, IL from April 28th to May 1st, 2023, to promote its asset ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia (“BPH”). Blue Water’s Chief Executive Officer, Joseph Hernandez, and Senior Vice Presi |
BWV Price Returns
| 1-mo | -23.08% |
| 3-mo | -28.57% |
| 6-mo | -30.43% |
| 1-year | -79.22% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -27.27% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |